Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TUBB | P07437 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10733419 | 0.88 | KMT2A (0.69) | HPGDCYP1A2CYP3A4CYP2C19KCNA5 | |
| SCHEMBL15621739 | 0.85 | KMT2A (0.62) | HPGDCYP3A4CYP2C19KMT2AHSP90AA1 | |
| SCHEMBL4500866 | 0.84 | HPGD (0.64) | HPGDCYP1A2CYP3A4CYP2C19KCNA5 | |
| SCHEMBL6356697 | 0.84 | HPGD (0.67) | HPGDCYP1A2CYP3A4CYP2C19KCNA5 | |
| SCHEMBL13236587 | 0.82 | TUBB (0.75) | HPGDCYP1A2CYP3A4CYP2C19KCNA5 | |
| SCHEMBL30100461 | 0.82 | TUBB (0.75) | HPGDCYP1A2CYP3A4CYP2C19KCNA5 | |
| SCHEMBL14741282 | 0.82 | HSP90AA1 (0.69) | HPGDCYP1A2CYP3A4CYP2C19KCNA5 | |
| SCHEMBL25045867 | 0.81 | HPGD (0.60) | HPGDCYP1A2CYP3A4CYP2C19KCNA5 | |
| SCHEMBL16982943 | 0.81 | HPGD (0.64) | HPGDCYP1A2CYP3A4CYP2C19KCNA5 | |
| SCHEMBL20354126 | 0.80 | HPGD (0.62) | HPGDCYP1A2CYP3A4CYP2C19KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557115-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1537089-A4 | COMPOUNDS COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1558083-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20080021050-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-7211580-B2 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060264449-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-11-23 | — | — | US | disclosed |
| EP-1558083-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1537089-A2 | COMPOUNDS COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040142949-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004034972-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004009036-A2 | COMPOUNDS COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021050-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | HPGD 1063/4885CYP1A2 4049/4885CYP3A4 4535/4885 |
| US-20060264449-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | HPGD 1063/4885CYP1A2 4049/4885CYP3A4 4535/4885 |
| US-20040142949-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | HPGD 1063/4885CYP1A2 4049/4885CYP3A4 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.